Parabilis Medicines (NASDAQ:PBLS) Rating Increased to Hold at Zacks Research

Parabilis Medicines (NASDAQ:PBLS) was upgraded by equities research analysts at Zacks Research to a “hold” rating in a report released on Tuesday,Zacks.com reports.

PBLS has been the topic of several other reports. Leerink Partners initiated coverage on Parabilis Medicines in a report on Monday. They issued an “outperform” rating and a $40.00 price objective on the stock. Guggenheim initiated coverage on Parabilis Medicines in a research report on Monday. They issued a “buy” rating and a $40.00 target price on the stock. Wall Street Zen raised Parabilis Medicines to a “hold” rating in a research note on Saturday, June 20th. Bank of America began coverage on Parabilis Medicines in a research report on Monday. They set a “buy” rating and a $45.00 price target for the company. Finally, Lifesci Capital raised Parabilis Medicines to a “strong-buy” rating in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $41.67.

Parabilis Medicines Price Performance

PBLS stock opened at $30.83 on Tuesday. Parabilis Medicines has a 52 week low of $24.51 and a 52 week high of $34.47.

Insider Buying and Selling

In related news, major shareholder Guy Levy purchased 500,000 shares of the company’s stock in a transaction dated Thursday, June 11th. The stock was acquired at an average cost of $20.00 per share, for a total transaction of $10,000,000.00. Following the completion of the transaction, the insider directly owned 1,027,000 shares of the company’s stock, valued at approximately $20,540,000. This trade represents a 94.88% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Alan Sebulsky purchased 12,500 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The stock was bought at an average cost of $20.00 per share, with a total value of $250,000.00. Following the acquisition, the director owned 12,500 shares of the company’s stock, valued at approximately $250,000. The trade was a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 530,000 shares of company stock worth $10,723,528 over the last three months.

Trending Headlines about Parabilis Medicines

Here are the key news stories impacting Parabilis Medicines this week:

• Positive Sentiment: Lifesci Capital upgraded Parabilis Medicines to Strong-Buy, signaling increased confidence in the company’s outlook and supporting the stock’s recent strength. Lifesci Capital upgrade report
• Positive Sentiment: Guggenheim initiated coverage with a Buy rating and a $40.00 price target, suggesting upside potential and helping boost investor sentiment. Guggenheim coverage report
• Positive Sentiment: Bank of America and Leerink Partners also began analyst coverage, adding to the positive Wall Street attention around PBLS. Bank of America coverage Leerink Partners coverage
• Neutral Sentiment: Lifesci Capital also published a full set of earnings estimates for 2026 and 2027, including expected losses for most quarters and fiscal years. While these forecasts provide more visibility, they do not appear to be a fresh catalyst by themselves. PBLS analyst estimates